Lung cancer has seen tremendous advances over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors, including several that are being applied outside of the advanced metastatic setting.

In a recent webinar hosted by Dr Jennifer Thompson, Oncology Medical & Scientific Affairs Manager at Roche Diagnostics Asia Pacific, a multidisciplinary panel of pathologists, surgeons and oncologists from Korea and Thailand share exciting updates in testing and treatments for early stage non-small cell lung cancer.